Department of Ophthalmology, Baylor College of Medicine, Houston, Texas.
Abrahamson Pediatric Eye Institute, Division of Pediatric Ophthalmology, Department of Neurology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.
JAMA Ophthalmol. 2020 Nov 1;138(11):1187-1191. doi: 10.1001/jamaophthalmol.2020.3322.
Pediatric pseudotumor cerebri syndrome pathophysiology is complex and not well delineated. Therefore, it is important to identify potential contributors or targets underlying the primary pathogenesis for its development.
To report cases highlighting the association of pediatric pseudotumor cerebri syndrome with adrenal insufficiency.
DESIGN, SETTING, AND PARTICIPANTS: This noncontrolled, observational case series included pediatric patients diagnosed with pseudotumor cerebri syndrome and adrenal insufficiency at an urban academic children's hospital in Houston, Texas, from June 2015 to October 2019.
Monitoring optic nerve edema by clinical examination, fundus photography, and optical coherence topography images of the optic nerve.
Data were collected from 5 pediatric patients (age range, 5-10 years) diagnosed with pseudotumor cerebri syndrome and adrenal insufficiency. One was a girl; all were White and prepubertal. Three patients had unrecognized glucocorticoid exposure. All patients had bilateral optic nerve edema that was initially treated with acetazolamide or topiramate, but cortisol functional testing by either 8 am cortisol or cosyntropin stimulation tests revealed a diagnosis of central adrenal insufficiency. Treatment with physiological doses of hydrocortisone resulted in resolution of optic nerve edema and clinical symptoms of pseudotumor cerebri syndrome, as well as a shorter time receiving medical therapy.
In this case series, adrenal insufficiency was associated with both primary and secondary prepubertal pediatric pseudotumor cerebri syndrome. As a potential target specific to causative mechanism, physiologic hydrocortisone therapy resolved the condition. To date, there remains a global unawareness among clinicians about the suppressive outcome that glucocorticoids may have on the developing hypothalamic-pituitary-adrenal axis, resulting in adrenal insufficiency and so-called episodic pseudotumor cerebri syndrome in young children. Ophthalmologists and pediatric subspecialists should implement cortisol testing via either 8 am cortisol or cosyntropin stimulation tests at initial evaluation of all children with pseudotumor cerebri syndrome and risk factors for adrenal insufficiency, no predisposing causes, or nonresponse to conventional treatment. Further management and treatment should be in combination with ophthalmology and endocrine services.
小儿假性脑瘤综合征的病理生理学较为复杂,尚未明确。因此,确定其主要发病机制的潜在致病因素或靶点非常重要。
报告病例以强调小儿假性脑瘤综合征与肾上腺功能不全之间的关联。
设计、地点和参与者:这项非对照、观察性病例系列研究纳入了 2015 年 6 月至 2019 年 10 月在德克萨斯州休斯顿市的一家城市学术儿童医院诊断为假性脑瘤综合征和肾上腺功能不全的儿科患者。
通过临床检查、眼底照相和视神经光相干断层扫描图像监测视神经水肿。
共纳入 5 例(年龄 5-10 岁)诊断为假性脑瘤综合征和肾上腺功能不全的儿科患者。其中 1 例为女性,均为白人且处于青春期前。3 例患者存在未被识别的糖皮质激素暴露。所有患者均存在双侧视神经水肿,最初采用乙酰唑胺或托吡酯治疗,但 8 点皮质醇或促皮质素刺激试验显示存在中枢性肾上腺功能不全。给予生理剂量的氢化可的松治疗后,视神经水肿和假性脑瘤综合征的临床症状得到缓解,且接受药物治疗的时间更短。
在本病例系列中,肾上腺功能不全与原发性和继发性青春期前小儿假性脑瘤综合征均相关。作为针对病因机制的特定靶点,生理剂量的氢化可的松治疗可缓解病情。迄今为止,全球的临床医生仍未意识到糖皮质激素可能对发育中的下丘脑-垂体-肾上腺轴产生抑制作用,导致肾上腺功能不全和所谓的儿童期发作性假性脑瘤综合征。眼科医生和儿科专家应在所有假性脑瘤综合征患儿和有肾上腺功能不全风险因素、无潜在病因或对常规治疗无反应的患儿的初始评估中实施皮质醇检测,检测方法可选择 8 点皮质醇或促皮质素刺激试验。进一步的管理和治疗应与眼科和内分泌科合作进行。